On October 26, 2023 MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported the details of two poster presentations at the 38th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, the world-leading event in immunotherapy, scheduled to be held from November 1-5, 2023, in San Diego, California, U.S.A (Press release, MaaT Pharma, OCT 26, 2023, View Source [SID1234636538]). Presentations will include in vitro results for its new Artificial Intelligence (AI)-generated lead product, MaaT034, designed to improve responses to immunotherapy for patients with solid tumors. MaaT034 is the first member of the MET-C platform that can co-cultivate a healthy microbiota ecosystem. The first-in-human testing is planned for 2025, with the first clinical batches to be produced in 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nathalie Corvaia, Chief Scientific Officer, states "we are very excited to present our first pre-clinical data at SITC (Free SITC Whitepaper) showing biological activity for MaaT034, our new generation of co-cultured products and the robustness of our proprietary AI-engine, gutPrint. MaaT034 is active in restoring the integrity of the gut barrier and stimulating immune cells leading to an improvement in the immune cell response to ICI therapy. This bolsters our confidence in our immuno-oncology approach driven by our AI engine. We are looking forward to moving to clinical evaluation in 2025."
Poster Presentation Details:
Poster 1 Title: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Poster Number: 1321
Date & Location: November 3, 2023 – Exhibit Halls A & B1
Key findings for MaaT034:
replicates, at large industrial scale, the richness and diversity of healthy native-based microbiome ecosystems
restores the integrity of a damaged gut barrier
activates AhR[1] pathway involved in gut homeostasis
stimulates both myeloid and lymphoid immune cells
improves immune cell response to ICI therapy
Poster 2 Title: Robust Machine Learning (ML) approach for screening Microbiome Ecosystem Therapies (MET) drug candidates in combination with Immune Checkpoint Inhibitors
Poster Number: 1304
Date & Location: November 3, 2023 – Exhibit Halls A & B1
Key findings for gutPrint AI engine:
selection and training of models to grade samples as "Responder-like" according to the baseline stool metagenomics of ICI treated cancer patients
improvement of predictive performance compared to literature with more patient data, cross studies and indication
application of the best performing model (mean LODO AUC = 0.65) to MaaT Pharma’s healthy donor cohort or pooled samples (mixes of stools from 4 to 8 healthy donors) classified a large majority of those as "Responder-like" microbiota (especially pooled samples)